Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Monday

Fulcrum Therapeutics (NASDAQ:FULC) is expected to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect Fulcrum Therapeutics to post earnings of ($0.29) per share for the quarter.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.01. On average, analysts expect Fulcrum Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Fulcrum Therapeutics Stock Down 0.7 %

NASDAQ:FULC opened at $5.37 on Friday. Fulcrum Therapeutics has a 52 week low of $2.32 and a 52 week high of $10.13. The firm has a 50 day moving average of $3.38 and a 200 day moving average of $3.70. The stock has a market capitalization of $289.87 million, a price-to-earnings ratio of -17.32 and a beta of 2.29.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “neutral” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $8.63.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.